Stroke has multiple etiologies, but the underlying genes and pathways are largely unknown. We conducted a multiancestry genome-wide-association meta-analysis in 521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 new stroke risk loci, bringing the total to 32. We further found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism, at individual loci (n = 18), and using genetic risk scores and linkagedisequilibrium-score regression. Several loci exhibited distinct association and pleiotropy patterns for etiological stroke subtypes. Eleven new susceptibility loci indicate mechanisms not previously implicated in stroke pathophysiology, with prioritization of risk variants and genes accomplished through bioinformatics analyses using extensive functional datasets. Stroke risk loci were significantly enriched in drug targets for antithrombotic therapy.
S
troke is the second leading cause of death and disabilityadjusted life years worldwide 1, 2 . Characterized by a neurological deficit of sudden onset, stroke is primarily caused by brain infarction (ischemic stroke) and, less often, by intracerebral hemorrhage (ICH). Common etiological subtypes of ischemic stroke include large-artery atherosclerotic stroke (LAS), cardioembolic stroke (CES), and stroke caused by small-vessel disease (small-vessel stroke (SVS)), which is also the leading cause of ICH. Previous genome-wide association studies (GWAS) in predominantly European-ancestry groups have identified ten loci robustly associated with stroke [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . In most instances, the associations with stroke were attributed to individual subtypes of ischemic stroke, such as LAS 5, 8, 9 , CES 3, 4 , and SVS 10, 12 , or of ICH 6 , although some loci were associated with two or more stroke subtypes 7, 9, 11, 13 or with any stroke 10 . We hypothesized that combining a substantially larger sample size with a transancestral analytic approach would identify additional risk loci and improve fine mapping of causal variants. Hence, we combined all available stroke samples with published or unpublished GWAS data, including samples of non-European ancestry that were underrepresented in previous GWAS. We further hypothesized that stroke shares genetic influences with vascular risk factors, intermediate phenotypes for stroke (for example, carotid artery plaque (cPL)), and related phenotypes (for example, coronary artery disease (CAD)) and that a systematic approach to identify genetic influences shared among these traits would provide insights into stroke pathophysiology.
Results
We tested ~8 million SNPs and indels with minor-allele frequency (MAF) ≥ 0.01 in up to 67,162 stroke cases and 454,450 controls for association with stroke. One analysis involved European participants only (40,585 cases; 406,111 controls), and a second involved participants of European, East Asian (17,369; 28,195) , African (5,541; 15,154), South Asian (2,437; 6,707), mixed Asian (365; 333), and Latin American (865; 692) ancestry (Fig. 1 ). Participants were drawn from 29 studies with genome-wide genotypes imputed to 1000 Genomes Project (1000G) phase 1v3 or similar 14 (MEGASTROKE consortium; Supplementary Note and Supplementary Tables 1 and 2 ). Ancestryspecific meta-analyses and subsequent fixed-effects transancestral meta-analyses and MANTRA transancestral meta-analyses were conducted 15 . Analyses were performed for any stroke (AS), comprising ischemic stroke, ICH, and stroke of unknown or undetermined type (n = 67,162); any ischemic stroke (AIS) regardless of subtype (n = 60,341); and ischemic stroke subtypes (LAS, n = 6,688; CES, n = 9,006; SVS, n = 11,710).
New genome-wide-significant stroke loci. We identified 32 genome-wide significant loci, 22 of which were novel (Table 1, Fig. 2,  Supplementary Tables 3 and 4 , and Supplementary Figs. 1-7 ). Of the 22 novel loci, 18 were identified by transancestral meta-analyses (fixed-effects P < 5.0 × 10 −8 or MANTRA log 10 (Bayes factor (BF)) > 6) ( Fig. 2 and Supplementary Figs. [1] [2] [3] [4] [5] , and the remaining four loci were identified by the ancestry-specific meta-analysis in European samples (fixed-effects P < 5.0 × 10 Table 1) . Comparison of the 32 loci across Europeans and East Asians, the two largest ancestral subgroups, demonstrated significant correlations of risk-allele frequencies and ORs between populations ( Supplementary Fig. 8 ), although six loci exhibited populationspecific association (defined as P < 5.0 × 10 −8 in Europeans and P > 0.05 in East Asians or MAF in East Asians < 0.01) (Supplementary Table 5 ). Estimates for the phenotypic variance explained by the 32 lead variants ranged between 0.6% and 1.8% (Supplementary Table 6 ).
Gene-based tests using VEGAS2 (ref. 16 ) ( Supplementary Fig. 9 ) confirmed the loci identified by the GWAS analyses above and yielded a novel significant (P < 2.02 × 10 , Bonferroni corrected for the number of genes) association of the neighboring genes ICA1L and WDR12 with SVS (Supplementary Table 7 and Supplementary  Figs. 9 and 10 ). Prior studies have demonstrated that variants in this region are associated with white-matter hyperintensity (WMH) burden 17 , a brain magnetic resonance imaging marker of smallvessel disease (SVD).
Twenty-one additional loci met a less stringent threshold for suggestive evidence of association (log 10 (BF) > 5.0 or P < 1.0 × 10 −6 in the transancestral fixed-effects analysis) (Supplementary Table 8) , including three loci previously implicated in Mendelian stroke (HTRA1, COL4A1, and COL4A2) Associations with etiological stroke subtypes. Genome-wide significance was reached for 18 loci (12 novel) for AS, 20 (12 novel) for AIS, 6 (3 novel) for LAS, 4 (2 novel) for CES, and 2 (ICA1L-WDR12 novel, discovered in gene-based tests) for SVS (Fig. 2 , Table 1 , and Supplementary Figs. 1-5 and 10). Several loci reaching genome-wide significance for one of the ischemic stroke subtypes were also genome-wide significant for AIS or AS, whereas none reached genome-wide significance for multiple ischemic stroke subtypes ( Fig. 2 and Supplementary Table 9 ). For some novel loci, the association was strictly confined to a single subtype (P > 0.5 for other stroke subtypes): EDNRA and LINC01492 showed association with LAS only, thus suggesting mechanisms limited to atherosclerosis, and NKX2-5 showed association with CES only, thus suggesting that the association may be primarily mediated by cardioembolism. We also found subtype specificity for previously described loci (TSPAN2 for LAS and PITX2 for CES). We further investigated shared genetic influences of individual loci on different stroke subtypes by using gwas-pw analyses 22 , which estimate the posterior probability that a specified genomic region influences two different traits. By applying a posterior-probability cutoff of 90% for shared contribution at a given locus (model 3), we found shared genetic influence between LAS and SVS at SH2B3, and between LAS and CES at ABO (Supplementary Table 10 and Supplementary Fig. 11 ).
Conditional analysis to identify independent signals within loci.
When conditioning all SNPs in a ± 0.5-Mb window on the lead SNPs in the Europeans-only analysis, we found two additional independent genome-wide signals at the PITX2 locus for CES, in agreement with known multiple independent loci at PITX2 for atrial fibrillation (AF) 23 , thus suggesting that a similar genetic architecture at this locus influences both conditions ( Supplementary Fig. 12 ). We further found suggestive independent signals at MMP12, SH2B3, and HDAC9-TWIST1 that did not reach genome-wide significance (Supplementary Table 11 ).
Association of individual stroke risk variants with related vascular traits. Several of our loci are in the genomic vicinity of established risk loci for vascular risk factors (for example, blood pressure (BP)), and related vascular phenotypes affecting the heart (for example, CAD), vasculature (for example, carotid intima media thickness (cIMT)), or the brain (WMH). To systematically explore the genetic overlap between stroke and these traits, we surveyed published GWAS for BP, blood lipids, type 2 diabetes (T2D), cIMT, cPL, AF, venous thromboembolism (VTE), CAD, and WMH, assembled through the IGEN-BP 24 , ENGAGE 25 , DIAGRAM 26 , CHARGE 27, 28 , AFGen Table 12 ). When constructing sets of index SNPs of the nonstroke phenotypes (Bonferroni-adjusted P < 1.3 × 10 −4 = 0.05/32 loci/12 related vascular traits) and SNPs in high linkage disequilibrium (LD) (r 2 > 0.9 in the 1000G Europeanancestry dataset (EUR)) with those index variants, 17 of the 32 stroke lead variants showed overlap with these sets (Fig. 3 and Supplementary Table 13 ). Fourteen loci reached genome-wide significance (P < 5.0 × 10
) for association with one or more of the following phenotypes: BP (five loci), CAD (five loci), AF (two loci), VTE (two loci), low-density liproprotein (LDL) cholesterol (two loci), cPL (one locus), and WMH (one locus). Among the 21 additional subthreshold loci for stroke (Supplementary Table 8 ), six loci have previously been associated with related vascular traits, including AF (PRRX and CAV1-CAV2) 32 , VTE (F11) 30 , CAD (SWAP70 and LPA) 31 , blood lipids (LPA) 31 , and WMH (ICA1L-WDR12) 28 .
Association of genetic risk scores of related vascular traits.
Second, we generated weighted genetic risk scores (wGRS) for VTE, BP-related traits, blood lipids, T2D, and CAD by using the lead SNPs from published GWAS and tested these wGRS for association with each stroke phenotype, implementing the inverse-variance weighting approach (Methods and Supplementary Table 14) . We found significant associations (P < 5.6 × 10 −3
, correcting for nine independent phenotypes; Methods) with wGRS for all traits examined, except for triglyceride and LDL-cholesterol levels, and observed clear differences between stroke subtypes (Fig. 4) . The strongest association was between the wGRS for CAD and LAS, in agreement with shared pathophysiology through atherosclerosis. We further found associations of all stroke subtypes with wGRS for BP traits. The wGRS for VTE was significantly associated with both LAS and CES (all P < 1.0 × 10 −4 ) but not SVS. The wGRS for high-density lipoprotein (HDL) cholesterol showed a significant inverse association with SVS.
In the present setting, the wGRS analysis was used primarily to explore the genetic overlap with related vascular traits rather than as a tool for establishing causal inference. In sensitivity analyses, we conducted an MR-Egger regression to explore whether any of the significant associations between vascular wGRS and stroke might be partly driven by directional pleiotropy. There was no indication of directional pleiotropy except for the association between the SBP wGRS and AS (MR-Egger intercept estimate P = 0.015), which was no longer significant after removal of 6 of 37 SNPs appearing as outliers from the leave-one-out analysis (Methods), thus leading to causal estimates in broad agreement across regression techniques (Supplementary Table 15 ).
Shared genetic contribution to stroke and related vascular traits genome wide. Third, we applied LD-score regression to quantify the extent of shared genetic contributions between traits at a genome-wide level 33, 34 . Using available GWAS results from individuals of European ancestry, we found significant positive correlations (r g > 0; P < 5.6 × 10
, correcting for nine independent phenotypes), mostly corroborating the wGRS results ( Fig. 4 and Supplementary Table 16 ). In addition, we found significant genetic overlap between triglyceride levels and AIS, and similar results were obtained in available GWAS datasets from individuals of East Asian ancestry (Supplementary Table 16 ). The results did not substantially change after removal of genome-wide signals for stroke and related vascular traits and their proxies (r 2 ≥ 0.8 in 1000G EUR).
Global epigenetic patterns at the 32 stroke risk loci. To test for cell-specific enrichment in chromatin marks that were previously shown to be phenotypically cell-type specific in the Encyclopedia of DNA Elements (ENCODE)/RoadMap (histone H3 modifications H3K4me1, H3K4me3, and H3K9ac) 35 , we implemented the epigwas tool 35 and the narrow peak information from the latest RoadMap dataset (127 tissues) 36 . Epigwas estimates the enrichment score (ratio of the height of the nearest narrow peak to the distance to the peak) for the lead variant and proxies (r 2 ≥ 0.8 in the 1000G cosmopolitan panel) and calculates statistical significance by examining the relative proximity and specificity of the test SNP set with 10,000 sets of matched background. The analysis showed significant enrichment of enhancer and promoter sites (marked by H3K4me1 and H3K4me3) in mesenchymal stem cells, embryonic stem cells, epithelial cells, and blood and T cells, and of active promoters (marked by H3K9ac) in embryonic stem cells and digestive tissue (Supplementary Table 17 ).
Pathway analyses.
To identify pathways overrepresented in the stroke association results, we used the DEPICT gene-set enrichment tool 37 , using all SNPs with log 10 (BF) > 5 for the respective stroke subtype. We found three gene sets to be significantly (false discovery rate (FDR) < 5%) associated with AS: enlarged heart, decreased cardiac muscle contractility, and oxaloacetate metabolic process (Supplementary  Table 18 ). Next, we used Ingenuity Pathway Analysis (IPA; URLs), examining genes within the 53 stroke loci with log 10 (BF) > 5. The extended gene list (r 2 > 0.5 in 1000G Europeans or East Asians, or located within 50 kb of the lead SNP) consisted of 214 genes. We found the coagulation system to be the most significant canonical pathway, followed by cardiomyocyte differentiation via bonemorphogenetic-protein receptors (FDR of 5%) (Supplementary  Table 19 ). Finally, we tested enrichment of VEGAS2-derived genebased P values in expert-curated and computationally predicted Biosystem gene sets
38
, adapting VEGAS2Pathway
39
, and identified significant association with 18 pathways, including various cardiac pathways, muscle-cell fate commitment, and nitric oxide metabolic process with CES (FDR of 5%) (Supplementary Table 20) .
Fine mapping derived from credible SNP-set analyses. To decrease the number of candidate variants per locus to the most noteworthy associations, we constructed 95% credible SNP sets for each of the 32 loci (lead SNP and proxy SNPs r 2 > 0.1 in 1000G panels), assuming one causal SNP per locus and uniform priors 40 . Credible SNP sets were generated in all stroke phenotypes and for European, East Asian, and African ancestries separately. We found a marked decrease in credible SNP sets for most loci, a result expectedly most pronounced for the phenotype showing the strongest association signal (Supplementary Table 21) . The greatest refinement was observed at RGS7, HDAC9-TWIST1, and SH2B3, where the lead SNP was the only SNP contained in the 95% credible set for the stroke phenotype showing the strongest association. We found that in 18 of the 32 stroke risk loci, the lead stroke risk variant either overlapped or was in moderate to high LD (r 2 > 0.8) with the most significant QTL variant for a nearby gene in at least one tissue or cell type (Supplementary Tables 22 and 23) . For seven loci, we observed association of the lead SNP and proxies with expression of a single gene (or methylation or protein level), sometimes the nearest gene (LRCH1, CDK6, CDKN2B, PRPF8, and MMP12), and sometimes a more distant nearby gene (ZCCHC14 for the ZCCHC14 locus, and TWIST1 for the HDAC9-TWIST1 locus), within the datasets explored. Associations were found primarily in stroke-relevant tissues and cell types, including vascular tissues, aortic endothelial cells, brain, blood, and immune cells. In most instances (11 loci, 61.1%), the risk SNP affected expression of multiple genes, thus suggesting that at individual loci, pleiotropic mechanisms, which might differ according to tissue/cell type, may in some instances influence stroke susceptibility 55, 56 . with one gene in stroke-relevant tissues, such as ZNF318 (6p21), AL049919 (12q24), and FES (15q26) in brain tissues (Supplementary  Tables 22 and 23) .
At some loci, meQTLs and eQTLs provided complementary information on the regulatory pattern. For instance, for the SH3PXD2A locus, SNPs in high LD with the lead stroke risk variant were found to be eQTLs for multiple genes (SH3PXD2A, SLK, GSTO1, GSTO2, and LOC729081), whereas several high-LD proxies (r 2 > 0.96) functioned as the most significant meQTL for CpG probes located in the promoter region of SH3PXD2A and not any of the other genes.
For the 149 genes located in the 32 genome-wide-significant loci (r 2 > 0.5 in Europeans or East Asians, or located ± 50 kb from the lead SNP; Methods), we assigned an empirical functional score based on the presence and number of eQTLs, meQTLs, pQTLs, and other biological criteria 57,58 (Methods and Supplementary 8.57
For each locus, the variant reaching the highest BF in the MANTRA or the lowest P value in the fixed-effects transancestral meta-analysis or the fixed-effects Europeans-only meta-analysis, respectively, is shown, and the respective stroke phenotype showing the strongest association is specified. Gene names in bold indicate that the variant is located within the gene; in other cases, the first gene corresponds to the closest gene, whereas additional gene names indicate eQTL signals from multiple studies, or from both eQTLs and meQTLs, or genes previously suspected to be causal (LDLR), with a maximum of two genes reported. The lead SNPs in ILF3-SLC44A2 and SMARCA-LDLR are in low LD (r 2 = 0.082). TRANS, MANTRA transancestral meta-analysis; EUR, Europeans-only fixed-effects meta-analysis; OR, odds ratio; CI, confidence interval; NA, not assessed; UTR, untranslated region. a rs146390073 did not meet the MAF threshold of 0.01 in samples other than those of European ancestry. b rs7610618: The transancestral meta-analysis results showed high heterogeneity (PP het = 0.96) and were thus excluded. Table 24 ), reasoning that genes with a higher functional score would be more likely to be causal, although this score requires validation by experimental data.
Joint modeling of epigenetic marks and association statistics.
In an additional approach to identify the most plausible causal variants and genes, we used RiVIERA 59 , which jointly models summary association statistics and corresponding epigenetic regulatory information in a Bayesian framework to estimate the posterior probability of association (PPA). RiVIERA uses the RoadMap epigenome data of 127 tissue types and information on chromatin (H3K4me1, H3K4me3, H3K36me3, H3K27me3, H3K9me3, H3K27ac, and H3K9ac) and DNA-accessibility (DNase I) marks. Three of the stroke risk loci (PMF1-SEMA4A, SH3PXD2A, and EDNRA) displayed a pattern in which the association statistics and epigenetic regulatory information jointly contributed to the modeling of the RiVIERA credible SNP set (the minimum number of SNPs whose PPA, accounting for both association statistics and epigenetic regulatory information, sum to ≥ 95%) ( Supplementary Fig. 13 ). The variants identified by RiVIERA as having the highest PPA were in moderate to high LD in the 1000G cosmopolitan panel with the respective lead SNP (rs7534434 for PMF1-SEMA4A, r 2 = 0.79 with lead SNP; rs11191829 for SH3PXD2A, r 2 = 0.99 with lead SNP; rs4835084 for EDNRA, r 2 = 0.35 with lead SNP). Two of these (at PMF1-SEMA4A and SH3PXD2A) were significantly enriched in RNA polymerase II binding in ENCODE cell types 60 , including H1 human embryonic stem cells ( Supplementary Fig. 13 ).
Enrichment in drug-target genes.
Given the previous evidence of the utility of GWAS in drug discovery and drug repositioning 57,61,62 , we evaluated the overlap between stroke-associated genes and known drug targets. Among the 149 genes located within the 32 stroke risk loci, 16 (11%) were registered as targets of currently approved drugs in the DrugBank database and the Therapeutic Target Database (Supplementary Table 25 ). Of these, two genes (FGA and PDE3A) were targets of approved drugs for antithrombotic therapy (ATC B01), i.e., alteplase, tenecteplase, reteplase, and anistreplase for FGA, and cilostazol for PDE3A (enrichment OR = 5.46, P = 0.0369; Fig. 5 ). This enrichment was strengthened after removal of the locus with the largest number of genes (SH2B3, 73 genes) (OR = 8.89, P = 0.0166) and after addition of 65 genes in 21 suggestive stroke risk loci (OR = 7.83, P = 0.00606).
Discussion
The current transancestral meta-analysis more than triples the number of stroke risk loci and identifies novel loci for AS, AIS, and all major subtypes of ischemic stroke. Our results highlight several major features of stroke genomics: (i) Approximately half of the identified stroke loci showed shared genetic association with other vascular traits, and the largest genetic correlation was found for blood pressure. We also identified shared genetic association with VTE, and distinct patterns of individual stroke subtypes provided further mechanistic insight. (ii) Eleven of the novel stroke risk loci (ANK2, CDK6, KCNK3, LINC01492, LRCH1, NKX2-5, PDE3A, PRPF8, RGS7, TM4SF4-TM4SF1, and WNT2B) suggest mechanisms not previously implicated in stroke pathophysiology; some of these suggest a strong link with cardiac mechanisms beyond those expected from established sources of cardioembolism. (iii) The 32 stroke risk loci were significantly enriched in drug targets for antithrombotic therapy-one for an approved thrombolytic drug (alteplase) and the other for an antiplatelet agent (cilostazol) approved for stroke prevention in Asia. (iv) Through incorporation of extensive functional datasets and bioinformatics analyses, we provide detailed information on prioritization of stroke risk variants and genes as a resource for further experimental follow-up. Most of the genome-wide associations were identified with both AS and AIS. Although this result relates in part to a greater statistical power compared with that in subtype analysis, we also found shared genetic influences between stroke subtypes, as exemplified by the gwas-pw analyses (SH2B3 and ABO). A notable finding was the identification of PMF1-SEMA4A as a risk locus for AIS. PMF1-SEMA4A is an established risk locus for nonlobar ICH 6 and thus is, to our knowledge, the first reported locus reaching genome-wide significance for ischemic as well as hemorrhagic stroke. PMF1-SEMA4A further reached genome-wide association for WMH burden 28 ( Fig. 3) , an established marker for SVD, and showed a strong signal in the SVS subtype, thus suggesting that the association with stroke is at least in part mediated by SVD. The underlying biological pathways do not seem to involve known vascular risk factors and may thus identify new targets for stroke prevention.
Among the novel loci showing associations restricted to specific stroke subtypes, EDNRA is consistent with atherosclerotic mechanisms, given its association with LAS, cPL 27 , and CAD 31 ( Fig. 3) . LINC01492 and the previously reported TSPAN2 locus likewise displayed associations restricted to LAS but showed no association with related phenotypes in our look-ups and in prior literature, thus evidencing mechanisms more specific for LAS. NKX2-5, showing association restricted to CES, has previously been reported as a genome-wide risk locus for heart rate and PR interval 63,64 but not consistently for AF 63, 65 , thus implicating cardiac mechanisms other than AF. Although the number of loci reaching genome-wide significance for association with SVS remained low, our results suggest an important role of common genetic variation in SVS. First, several of the associations with AS or AIS, including those at novel loci (CASZ1, LOC100505841, SH3PXD2A, and ICA1L-WDR12), showed predominant association with the SVS subtype (Supplementary  Tables 7 and 9 ). Second, three of the top loci (PMF1-SEMA4A, LOC100505841, and SH3PXD2A) showed genetic overlap with Loci reaching genome-wide significance for association with stroke subtypes are marked with a dagger symbol (for CES), underlined (for LAS), or marked with an asterisk (for SVS). Novel loci are in bold. SH3PXD2A, WNT2B, PDE3A, and OBFC1 have previously been associated with AF (SH3PXD2A) 65 , or diastolic (WNT2B and PDE3A) 24, 72 or systolic (OBFC1) 73 BP, but the respective lead SNPs were in low LD (r 2 < 0.1 in the 1000G cosmopolitan panel) with variants associated with stroke in the current GWAS. MRI, magnetic resonance imaging; IMT, intima-media thickness; LDL, low-density lipoprotein; HDL, high-density lipoprotein. The lead variant for TBX3 is not included in the original datasets for BP traits (SBP and DBP). Results are based on a perfect proxy SNP (rs35432, r 2 = 1 in the European 1000G phase 3 reference).
loci for WMH. Third, several suggestive loci (log 10 (BF) ≥ 5) for AS and SVS contained genes implicated in monogenic SVD (HTRA1, COL4A1, and COL4A2) (Supplementary Table 8 ).
Our extensive exploration of shared genetic variation between stroke and related vascular traits found the most widespread correlations with BP phenotypes, in agreement with epidemiological data showing that high BP is the leading risk factor for stroke. A quarter of the 32 genome-wide-significant stroke loci were BP loci, most of which were novel with respect to stroke risk and showed association with risk of AS or AIS. Aside from the expected genetic overlap between LAS and CAD, we identified significant overlap between a wGRS for VTE and both LAS, and CES, but not SVS (Fig. 4 and Supplementary Table 14) despite a greater statistical power for this subtype, thus potentially suggesting that thrombotic processes play a less important role in SVS.
Three of our novel loci (NKX2-5, ANK2, and LRCH1) have previously been associated with cardiac pacing 63, 64, 66 . NKX2-5 and ANK2 have been further implicated in familial forms of cardiac disease [67] [68] [69] [70] , but none of the three loci were associated with AF or CAD in the latest published GWAS 31, 65 . Apart from NKX2-5, these loci were not specifically associated with CES, thus possibly indicating an involvement of the underlying genes in roles beyond cardiac development and function. rs9526212, the lead variant in LRCH1, was an eQTL for LRCH1 in multiple tissues, including the left ventricle, atherosclerotic aorta, atherosclerotic-lesion-free arteries, and blood (Supplementary Table 22 ). Pathway analyses further supported a strong link with cardiac mechanisms.
The extensive in silico functional annotation of identified stroke risk loci provides informative elements for future prioritization and follow-up of the most compelling biological candidates. In some instances, the eQTL, meQTL, and pQTL information strongly supports involvement of one gene over others in the region, for example, for SH3PXD2A, encoding SH3 and PX-domain-containing protein 2A, an adaptor protein involved in formation of invadopodia and podosomes as well as extracellular-matrix degradation. For some loci, joint analysis of epigenetic regulatory effects and association statistics enabled prioritization of credible SNPs. When exploring the overall epigenetic patterns of identified stroke risk loci, we observed some enrichment in enhancer and promoter sites in developmental tissues, thus suggesting that some associations may be driven by developmental effects, as has recently been proposed for the FOXF2 locus 10 . RGS7 and TM4SF4-TM4SF1 showed low MAFs, high heterogeneity, poor imputation quality in non-Europeans, and large effectsize estimates, and they must therefore be interpreted with caution. Moreover, although our extensive functional exploration provides guidance on gene prioritization for further exploration, additional experiments are required to identify the causal genes and variants. Several studies have provided limited information on stroke subtypes. Hence, the sample sizes for ischemic stroke subtypes were still relatively small. In addition, the proportion of the phenotypic variance explained by the 32 lead SNPs was relatively small but comparable to that in other complex diseases 71 . Collectively, these aspects highlight the potential for gene discovery in the future.
In conclusion, we identified 22 novel stroke risk loci and demonstrated shared genetic variation with multiple related vascular traits. We further identified new loci offering mechanisms not previously implicated in stroke pathophysiology and provided a framework for prioritization of stroke risk variants and genes for further functional and experimental follow-up. Stroke risk loci were significantly enriched in drug targets for antithrombotic therapy, thus highlighting the potential of stroke genetics for drug discovery. Collectively, these findings represent a major advance in understanding the genetic underpinnings of stroke.
URLs. Ingenuity Pathway Analysis, https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/.
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Methods
Study design and phenotyping.
A detailed description of the study design, participating studies, and phenotype definitions for stroke and stroke subtypes is provided in the Supplementary Note. Characteristics of study participants are shown in Supplementary Table 2 for each study. All participants provided written informed consent, and local research ethics committees and institutional review boards approved the individual studies.
Genotyping, imputation, and quality control. Genotyping platforms and imputation methods for each participating study are described in Supplementary  Table 2 . All studies used imputed genotypes based on at least the 1000G phase 1 multiancestral reference panel and conducted logistic regression analyses (or Cox regression for longitudinal population-based cohort studies) for five stroke traits (AS, AIS, LAS, CES, and SVS) with all measured and imputed genetic variants in dosage format by using appropriate software under an additive genetic model with a minimum of sex and age as covariates. Information on additional covariates is given in Supplementary Table 2 .
Before ancestry-specific meta-analysis, QC was performed on each study by two independent researchers following a standardized protocol based on the suggestions of Winkler et al.
74
. Marker names and alleles were harmonized across studies. Meta-analyses were restricted to autosomal biallelic markers from the 1000G phase 1 v3. Duplicate markers were removed from each study. P-Z plots, QQ plots and allele-frequency-plots were constructed for each study. After visual inspection, analysis and QC were repeated if deemed necessary. QC was conducted independently for all participating studies in at least two sites.
Individual study-level filters were set to remove extreme effect values (β > 5 or β < -5), rare SNPs (MAF < 0.01) and variants with low imputation accuracy (oevar_ imp or info score < 0.5). The effective allele count was defined as twice the product of the MAF, imputation accuracy (r 2 , info score or oevar_imp), and number of cases. Variants with an effective allele count < 10 were excluded 74 . The number of SNPs passing QC for each study is given in Supplementary Table 26 .
Genome-wide-association meta-analyses. The overall analytical strategy is shown in Fig. 1 . We first conducted fixed-effects inverse-variance-weighted meta-analysis with METAL 75 in each ancestral group (EUR, EAS, AFR, SAS, LAT, and other ASN), then performed meta-analysis of the ancestry-specific metaanalysis results. We constructed two versions of each meta-analysis: one with single genomic control applied and one without genomic control (for LD-score regression analysis).
The EUR-specific and transancestral fixed-effects meta-analyses were further filtered for heterogeneity (P het < 5.0 × 10
) and for the number of cases included for a specific marker (< 50% of stroke cases were excluded). In addition, we ran a transancestral GWAS meta-analysis, using MANTRA 15 , which was based on ancestry-specific meta-analysis results. The final MANTRA results were filtered for a MANTRA posterior-probability heterogeneity P < 0.95. SNPs with log 10 (BF) > 6 were considered to be genome-wide significant, whereas SNPs with 6 > log 10 (BF) > 5 were considered to show suggestive association. We used a method based on summary statistics 76 to estimate the variance in liability explained by each lead variant. Disease prevalence was set to 5.5% for AS, to 4.4% for AIS, and to 0.11% for IS subtype in Europeans 77 . Disease prevalence was set to 2.97% for AIS, to 0.91% for LAS, to 0.24% for CES, and to 1.76% for SVS in East Asians (Hisayama study, J. Hata unpublished data and ref. 90 ). We used summary statistics from the Europeans-only fixed-effects meta-analysis and the East Asian-only fixed-effects meta-analysis. Genomic inflation was calculated as lambda in the GenABEL package (available through CRAN repositories). In addition, we calculated the LD-score-regression intercepts for the Europeans-only fixed-effects meta-analysis, using European LD scores.
Shared genetic influences of individual loci on mechanistically defined stroke subtypes. We used gwas-pw 22 to detect shared genetic influences of LAS, CES, and SVS, aiming to identify genetic variants that influence respective pairs of these traits. Gwas-pw estimates the PPA for four models. Model 3 is the model in which a given genomic region contains a genetic variant that influences both traits. We used the fixed-effects transancestral meta-analysis results as input, transforming results into signed Z scores based on the P value and sign of the log(OR). The chunk size (number of SNPs included in each chunk analyzed) was set automatically by using an approximately independent block file (ld-select), as provided by the software. Correlation was set to reflect the overlap in controls. We deemed the results of model 3 with a PPA > 0.9 significant 22 .
Conditional analysis. We used GCTA-COJO 78 to perform conditional association analysis in each of the stroke loci in Europeans. We first fit a stepwise joint regression model including all SNPs with joint P < 5.0 × 10
. In instances in which regions included only one SNP, we fit a model including the top two SNPs from each region. The models made use of (i) summary statistics from the Europeansonly meta-analysis presented herein and (ii) genotype data for 3,291 stroke cases and 11,820 controls of North European ancestry from NINDS-SiGN as an LD reference for each region.
Gene-based analysis. We performed gene-based tests by using the VEGAS approach 79 implemented in VEGAS2 software 16 . We used 24,769 autosomal refseq genes to perform gene-based association studies. To perform gene-based association tests, we used the 1000G phase 3 super populations African (AFR), East Asian (EAS), European (EUR), American (AMR) and South Asian (SAS) as a reference to compute the pairwise LD between variants residing within a gene. We performed gene-based tests, using the '-top 10' parameter in VEGAS2, which tests enrichment of the top 10% of association P values within a gene. To maintain specificity while including cis-regulatory variants, we included variants located within 10 kb of a gene's 3′ and 5′ UTRs. We performed 1 × 10 6 simulations to compute empirical P values for association with each gene. For genes with P < 1 × 10 −5 , we increased the number of simulations to 1 × 10 8 to increase the accuracy of the association P values. For individual stroke subtypes, we performed ancestry-specific gene-based association followed by meta-analysis of gene association P values by using Stouffer's method, based on sample size.
Association of individual stroke risk variants with related vascular traits.
We systematically explored genetic overlap with AF, CAD, cIMT, cPL, diastolic BP, systolic BP, HDL-cholesterol levels, LDL-cholesterol levels, triglyceride levels, T2D, VTE, and WMH. First, we acquired summary statistics from the appropriate consortia (Supplementary Table 12 ). For each of the nonstroke phenotypes, we constructed a SNP set including the index variant of the nonstroke phenotype with P < 1.3 × 10 −4 plus all variants in high LD (r 2 in 1000G EUR > 0.9 with this index variant). If the MEGASTROKE lead SNP was included in this set of SNPs, we deemed the overlap with the nonstroke phenotype to be significant. We show two different tiers: (i) variants that showed genome-wide significance in the related vascular trait (P < 5.0 × 10
) and (ii) variants that were not genome-wide significant but passed Bonferroni correction (P = 1.3 × 10
−4
).
Association of genetic risk scores of related vascular traits with stroke and stroke subtypes. Genetic risk scores generated from variants shown to have genome-wide association with various vascular risk factors (VTE, DBP, SBP, MAP, PP, HTN, HDL cholesterol, LDL cholesterol, triglycerides, T2D, and CAD) were used to estimate the overlap between vascular traits and stroke and its subtypes. The effect allele for each risk-factor variant was defined as the allele associated with increased risk-factor levels. The corresponding allele information, β coefficients and standard errors from different stroke subtypes were extracted and used as input. Association was tested with the inverse-variance weighting (IVW) method implemented as an R package gtx V 0.0.8 (available through CRAN repositories).
We further conducted sensitivity analyses, using the MR-Egger method implemented as an R package (TwoSampleMR, available through CRAN repositories) 80 , which, unlike the IVW method, estimates the intercept term as part of the analysis. An intercept term significantly differing from zero suggests the presence of directional pleiotropy. We used a conservative significance threshold of P < 0.05 for the intercept. In the presence of directional pleiotropy, leave-one-out analysis was carried out by retesting the association of the vascular GRS with the outcome (stroke), leaving out each SNP in turn to determine whether a single SNP drives the association. We manually identified outlier SNPs that might drive the observed directional pleiotropy and then repeated the analyses (IVW and MR-Egger) after excluding the variants exhibiting directional pleiotropy.
The selection of SNPs for the vascular GRS was based on literature (PubMed) searches and the GWAS catalog (http://www.ebi.ac.uk/gwas/), and was used to identify studies that performed GWAS of the various risk factors. The most recent and largest GWAS of each risk factor was selected, and the associated variant details were retrieved. For the GRS analysis, only independent variants (r 2 < 0.01, based on the 1000G EUR panel) were used for the analysis (Supplementary Table 27 ). Risk-variant selection for BP traits (SBP, DBP, MAP, and PP) was further extended to studies with gene-centric chips. We used β coefficients extracted from the summary statistics of the International Consortium of BP GWAS 81, 82 as weights for this GRS analysis. A P-value < 5.6 × 10 −3 correcting for nine independent phenotypes was considered significant. The number of independent vascular phenotypes, taking into account the correlation between the phenotypes considered, was estimated on the basis of individual-level data from the 3C study by using the online tool matSpDlite (http://neurogenetics. qimrberghofer.edu.au/matSpDlite/).
Shared genetic contribution to stroke and related vascular traits at the genomewide level. We used LD-score regression to estimate the genetic correlation between stroke and related vascular traits 33, 34 . We conducted analyses on the European and East Asian stroke GWAS summary statistics only. Summary statistics from the GWAS meta-analyses for vascular risk factors and intermediate or related vascular phenotypes (BP, blood lipids, T2D, cIMT, cPL, AF, VTE, CAD, and WMH) were acquired from the respective consortia, as detailed in Supplementary Table 12 . For LD-score regression in East Asians, we further received prepublication access to summary statistics of GWAS for blood lipids conducted in BioBank Japan 91 , as described in the Supplementary Note. For each trait, we filtered the summary statistics to the subset of HapMap 3 SNPs to decrease the potential for bias due to poor imputation quality. Analyses were performed separately by using summary statistics from the European-and East Asian-specific meta-analysis. We used the European or East Asian LD-score files calculated from the 1000G reference panel and provided by the developers. A P value < 5.6 × 10 −3 correcting for nine independent phenotypes was considered significant. All analyses were performed with the ldsc package (https://github.com/bulik/ldsc/).
Global epigenetic patterns at the 32 stroke risk loci. We used the epigwas tool 35 to test for cell-specific enrichment in chromatin marks that have previously been shown to be phenotypically cell-type specific in ENCODE and/or RoadMap epigenome data (H3K4me1, H3K4me3, and H3K9ac) 35 , leveraging the recent release of ENCODE/RoadMap epigenome data from 127 tissue types 36 . Histone ChIP-seq data for narrow contiguous regions of enrichment were used to calculate the enrichment score (height of the nearest tall peak/distance to the peak) for the lead variant and proxies (r 2 > 0.8 in the 1000G cosmopolitan panel). Significance was estimated by examining the relative proximity and specificity of the test SNP set with 10,000 sets (permutation) of matched background. In addition, Bonferroni correction for the number of chromatin marks tested was applied.
Pathway analyses. To identify pathways overrepresented in the stroke association results, we used data-driven expression-prioritized integration for complex traits (DEPICT 37 ), IPA (https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis/), and VEGAS2Pathway
39
. DEPICT version 1 release 194 was used to identify biological pathways, tissues, and cell types enriched among suggestive associations (log 10 (BF) > 5) for any stroke and stroke subtypes in the MANTRA transancestral GWAS. Results are presented for the MANTRA transancestral analysis. We deemed DEPICT pathways with an FDR < 0.05 statistically significant.
IPA was conducted by using an extended list comprising 214 genes located in the boundaries defined by r 2 > 0.5 with the lead SNP in Europeans or East Asians, or located + 50 kb from the lead SNP, for all suggestive loci reaching P < 1.0 × 10 −5 or log 10 (BF) > 5 (Supplementary Table 25 ). This gene list was taken as an input for IPA using only findings from human and experimentally verified results. Otherwise, standard parameters were used for the analysis. We corrected canonical pathway P-value analysis with the Benjamini-Hochberg method and deemed an FDR < 0.05 significant.
We performed gene-wide gene-set enrichment analysis, using the VEGAS2Pathway approach 39 to test which Biosystem terms 38 were enriched with VEGAS2-derived gene association P values for stroke subtypes. VEGAS2Pathway performs a competitive gene-set enrichment test while accounting for gene density in LD blocks (or correlated association P values of neighboring genes), SNP density, and pathway size by using a resampling strategy.
For individual stroke subtypes, we performed separate ancestry-specific geneset enrichment analysis. Next, we combined the gene-set-enrichment association P values across ancestries by using Stouffer's method for sample-size-weighted combinations of P values. For each stroke subtype, we tested the association of 9,981 Biosystem gene-set terms.
Fine mapping derived from credible SNP-set analyses. We implemented the method of Maller et al. 83 , converting our ancestry-specific meta-analysis P values to Bayes factors through Wakefield's approximation 40 in all stroke phenotypes in the EU-only, EAS-only, and AFR-only analysis. We used all SNPs in LD with the lead SNP (r 2 > 0.1, ancestry specific). The Bayes factors were then used to calculate posterior probabilities on the basis of the assumption of a single causal SNP in each region. For all regions, we constructed 95% credible sets of potentially causal SNPs.
Investigation of eQTLs, pQTLs, meQTLs, and regulatory marks in different tissues. The following datasets, covering a large variety of tissue and cell types, were interrogated for eQTLs, pQTLs, and meQTLs:
1. The Genotype-Tissue Expression (GTEx-V6) project data, providing significant eQTL information from 44 postmortem tissues (449 individuals) (http://biorxiv.org/content/early/2016/09/09/074450/), with significance based on a gene-specific P-value threshold that is permutation-adjusted for multiple SNPs per gene 2. The Genome-wide Repository of Associations between SNPs and Phenotypes, build 2.0 (GRASP2) 46, 47 , as well as a collected expression and epigenetic QTL database of > 100 sources covering a wide range of cell and tissue types (Supplementary Note), using P < 5 × 10 −6 as a significance threshold for association with expression of a transcript in the original study 3. The Human Genetic Variation Database (HGVD) 48 , providing eQTL information from peripheral-blood cells in a Japanese population (n = 1,208), with significance defined by FDR < 5% 4. The Biobank-based Integrative Omics Studies (BIOS), providing eQTLs from peripheral-blood RNA-seq data in 2,116 unrelated individuals 49 , with significance defined by FDR < 5% 5. A subset of the Blueprint epigenome project 50 with eQTL, meQTL, and histone-modification data (H3K4me1 and H3K27ac) in CD14 + monocytes, CD16
+ neutrophils, and CD4 + naive T cells from 197 individuals; these were mapped through the classical QTL association test, allele-specific-expression test, and combined haplotype test, with significance defined by FDR < 5% 6. The Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task study (STARNET) 51 , providing eQTL data from vascular and metabolic tissues in 600 patients with CAD, with Benjamini-Hochberg-corrected association P values (P < 0.05) 7. The aortic endothelial cell study 52 , providing eQTL data from human aortic endothelial cells in 147 individuals, with Bonferroni multiple testing correction for the number of independent SNPs (P < , measuring 1,124 proteins on the SomaSCAN platform in 1,000 participants; significance for each association was set at P < 5.0 × 10
In each of these datasets, we report the most significant cis-QTL, meQTL, or pQTL surpassing a study-specific predefined significance level or FDR, considering only QTLs in LD with the lead stroke SNP at an r 2 > 0.8 (in 1000G, as well as queries of multiple builds of SNAP 84 Table 22 ). In addition, we also systematically report the association of the top QTL with stroke risk and of the lead stroke risk variant with the corresponding transcript expression, methylation level, or protein level (Supplementary Table 23 ).
In addition, we used a subset of the Blueprint epigenome project in CD14 + monocytes, CD16 + neutrophils, and CD4 + naive T cells from 197 individuals 50 and Haploreg V4 (ref.
86
) to annotate the lead variants and proxies for enrichment in specific histone-modification marks for the chromatin state, on the basis of ChIP-seq data from multiple cell/tissue types from ENCODE 87 and NIH RoadMap epigenome 36 . The results for each of the lead SNPs and its proxies are displayed in detail in Supplementary Table 22 .
Integration of association statistics and in silico functional information in RiVIERA-beta. To identify the most plausible causal variants and genes, we used RiVIERA software 59 , which jointly models the summary association statistics and the corresponding epigenetic regulatory information in a Bayesian framework to estimate the PPA. The empirical prior of a variant to be associated with the respective trait through regulatory features was generated by using the 848 tissuespecific epigenomic data in seven chromatin (H3K4me1, H3K4me3, H3K36me3, H3K27me3, H3K9me3, H3K27ac, and H3K9ac) and DNA-accessibility (DNase I) marks from the ENCODE/RoadMap epigenome data. Binary epigenomic annotation matrices of a variant overlapping the narrow peaks were generated. For inferring the causal region, RiVIERA-beta performs a repeated (n = 1,000) random-sampling step per locus, with the step size set to 1.0 × 10 . Iteration is performed until convergence (acceptance rate > 60%) is achieved, which is critical for the accurate estimation of PPA. We generated 95% credible sets in each region on the basis of the PPA. Regional plots were generated by using the association statistics and the PPA. Epigenetic enrichment over a fixed window size (50 bp) per tissue group was generated by taking the cumulative sum of empirical prior weighted global epigenetic enrichment. Tissues were divided into 19 groups, as defined in the NIH RoadMap epigenome project.
Scoring method. To prioritize the most likely biological-candidate genes, we integrated functional and biological information into an empirical score for each of the genes residing in the 32 genome-wide-significant loci. These comprised 149 genes within the region defined by an r 2 > 0.5 in any of the 1000G European or East Asian populations or physical distances of ± 50 kb from the lead SNP of the respective locus (Supplementary Table 25 ). A score of 1 was assigned for being the nearest gene to the lead SNP, for containing a missense variant, for containing histone-mark H3K4me3, H3K9ac, and H3K4me1 peaks in cell types that showed significant enrichment in epigwas analysis, and for functioning as an eGene for an eQTL, meQTL, or pQTL (one point for each) in at least one study and one cell/tissue type. In addition, a score of 1 was assigned for each stroke phenotype showing evidence of being a drug-target gene in the DrugBank database (ATC-C and ATC-B01) and the Therapeutic Target Database (Supplementary  Table 25 ), and for overlap with biological pathways in DEPICT, IPA, or VEGAS2 (Supplementary Tables 18-20) .
Drug-target gene-enrichment analysis. For each locus containing a variant with log 10 (BF) > 5 in the MANTRA analysis, we annotated the genes by considering LD structures (r 2 > 0.5 in any of 1000G EUR or ASN populations) or physical distances (± 50 kb) from the lead SNP of the respective locus. Drug-target genes were extracted from the DrugBank database 88 (considering those registered as pharmacological active targets; https://www.drugbank.ca/) and Therapeutic Target Database 89 (TTD; http://bidd.nus.edu.sg/group/cjttd/TTD_HOME.asp), thus resulting in a list of 1,123 genes (and corresponding proteins) annotated to currently approved drugs indicated for any diseases (Supplementary Table 25 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Ascertainment criteria for each study in MEGASTROKE are given in the Supplementary Note, Section 3.
1. An overview of population characteristics for each study can be seen in Supplementary Table 2 . Due to the extensive nature of these data, please refer to this table.
